October 13, 2008 – Neuronascent, Inc. announced that the Company has received funding from multiple sources to further the development of its novel, neurogenic compounds targeting Alzheimer’s disease, depression and ischemia......The company’s lead compounds, currently in preclinical testing, aim to replace damaged neurons, restore neurons critical to cognition and memory and enhance neuroprotection against neurodegenerative diseases. Results from recent animal studies show a reversal of cognitive loss in aged mice to young levels... [PDF] Neuronascent's Press Release -
